New data published by InCrowd has suggested that US physicians are very amenable to the prescription of biosimilars, with some believing that that they will become the norm in the next three years.
The results of the survey of targeted US biologics prescribers reflect a growing trend towards the use of biosimilars, efficacy and safety considerations notwithstanding, due to lower patient costs. Nearly half of the doctors surveyed anticipate that, with the availability of biosimilars increasing, their prescribing of biosimilars will expand in the next three years. Citing lower costs as a key driver, one in four physicians indicated that payers and insurance firms will ultimately determine, if not mandate, their level of biosimilar prescribing over the next three years.
Other key findings of the survey include:
One dermatologist who responded to the study writes: “If they are equally effective and cheaper, it’s tough to see a downside”. An oncologist echoed these views, indicating: “Biosimilars will be cheaper. If the efficacy is there and the price is better, then why not?”
Diane Hayes, PhD, president and co-founder of InCrowd, comments: “As the healthcare industry grapples with the best strategies to lower drug costs, the MicroSyndicated survey shows that while understandably prioritising efficacy and safety first, physicians are on board with their use. They key will lie in how payers decide to reimburse for biosimilars and their biologic counterparts.”
The survey itself captured data from 150 US-based board-certified physicians working in specialities where biologics prescribing is significant, including endocrinology, gastroenterology and oncology.
As we have highlighted before, the US has lagged behind European progress on biosimilars. While the first biosimilar drug hit the European market in 2006, regulation allowing biosimilars to fully reach the US market only began to gather pace with Obama’s Patient Protection and Affordable Care Act in 2010. With $70 billion worth of patents due to expire in 2020, we predicted that 2016 could be a year when the biosimilar floodgates open in America. According to this new survey, this may in fact be the case.
By Sean Murray
Source: PharmaFile
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
